物流服务提供商DHL Group完成对CryoPort专业快递业务CRYOPDP的收购-动脉网

Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group

CISION 等信源发布 2025-06-12 19:59



可切换为仅中文







NASHVILLE, Tenn.

田纳西州纳什维尔

，

June 12, 2025

2025年6月12日

/PRNewswire/ --

Cryoport, Inc.

Cryoport公司

(Nasdaq:

（纳斯达克：

CYRX

赛雷克斯

) ('Cryoport' or the 'Company'), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a focus on regenerative medicine, today announced the completion of the previously disclosed divestiture of its specialty courier business, CRYOPDP, to DHL Group ('DHL'), one of the world's leading logistics providers, in a transaction that includes cash payments of approximately .

）（“Cryoport”或“公司”），生命科学领域温控供应链解决方案的领导者，专注于再生医学，今天宣布已完成此前披露的将其专业快递业务CRYOPDP剥离给DHL集团（“DHL”）的交易，DHL是全球领先的物流供应商之一，该交易包括约的现金支付。

$200 million

2亿美元

to Cryoport.

致Cryoport。

Concurrently, Cryoport and DHL have established a strategic partnership aimed at enhancing their respective supply chain service offerings for the global life sciences and healthcare sector. This newly formed strategic partnership enables the companies to collaborate on strategic opportunities, leveraging Cryoport's industry-leading expertise in specialized supply chain solutions with DHL's expansive global health logistics infrastructure and services, bringing an array of specialized pharma logistics and services to the rapidly growing life science and healthcare market segment..

同时，Cryoport 和 DHL 已建立战略合作伙伴关系，旨在加强各自在全球生命科学和医疗保健领域的供应链服务。这一新形成的战略伙伴关系使两家公司能够就战略机遇进行合作，结合 Cryoport 在专业供应链解决方案中的行业领先专长与 DHL 广泛的全球健康物流基础设施和服务，为快速增长的生命科学和医疗保健市场领域提供一系列专业的医药物流和服务。

Jerrell Shelton

杰里尔·谢尔顿

, CEO of Cryoport, commented, 'Our strategic partnership and this transaction mark a significant step that contributes to the continued evolution of our industry and aligns with Cryoport's long-term strategic vision. With this partnership, we are enhancing our core capabilities as we develop a strong global partner network.

Cryoport首席执行官评论道：“我们的战略伙伴关系及此次交易标志着对行业持续发展的重要一步，也符合Cryoport的长期战略愿景。通过这一合作，我们正在增强核心能力，并建立强大的全球合作伙伴网络。”

We believe this partnership with DHL will enhance our positioning in the .

我们相信，与DHL的这种合作关系将增强我们在市场中的地位。

Asia Pacific

亚太地区

('APAC') and

('亚太地区') 和

Europe

欧洲

，

Middle East

中东地区

and

和

Africa

非洲

('EMEA') regions where it will reshape our competitive profile. It provides for greater opportunities to offer highly targeted, top-tier services in these regions in response to growing market demand. Most importantly, it allows us to intensify our focus on advancing our Life Science Services platform globally, particularly in the rapidly growing Regenerative Medicine market..

（'EMEA'）地区，这将重塑我们的竞争格局。它为我们提供了更多机会，在这些地区提供高度针对性的顶级服务，以响应不断增长的市场需求。最重要的是，它使我们能够加强在全球范围内推进生命科学服务平台的关注，特别是在快速增长的再生医学市场。

'This strategic partnership and divestiture of CRYOPDP delivers a healthy capital infusion, improves our growth trajectory and places us in a solid position to reach our goal of sustainable, long-term profitability.'

“这一战略合作伙伴关系及剥离CRYOPDP带来了健康的资本注入，改善了我们的增长轨迹，并使我们处于实现可持续、长期盈利目标的坚实位置。”

Additional information on the transaction will be available in the Company's current report on Form 8-K that will be filed with the Securities and Exchange Commission ('SEC').

有关该交易的更多信息将在公司将向证券交易委员会（“SEC”）提交的8-K表格当前报告中提供。

About Cryoport, Inc.

关于Cryoport公司

Cryoport, Inc.

Cryoport公司

(Nasdaq:

（纳斯达克：

CYRX

赛雷克斯

), is a global leader in temperature-controlled supply chain solutions for the Life Sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the Life Sciences.

），是生命科学领域温度控制供应链解决方案的全球领导者，专注于再生医学。我们为生物制药公司、合同制造商 (CDMO)、合同研究组织 (CRO)、开发者和研究人员提供全面的服务和产品，旨在将生命科学领域温度控制供应链中的风险降至最低，同时提高可靠性。

Our integrated supply chain platform includes the Cryoportal.

我们的集成供应链平台包括Cryoportal。

Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized biologistics, biostorage, bioservices, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are .

物流管理平台、先进的温控包装、信息学、专业的生物物流、生物储存、生物服务和低温系统，以不同的组合提供满足生命科学严格要求的端到端解决方案。创新、法规遵从性和敏捷性是我们核心的价值。

'Enabling the Future of Medicine™.'

“开启医学的未来™。”

Our corporate headquarters, located in

我们的企业总部位于

Nashville, Tennessee

田纳西州纳什维尔市

, is complemented by global sites in the Americas, EMEA, and APAC, including locations in

，在美洲、欧洲中东非洲（EMEA）和亚太地区（APAC）的全球站点作为补充，包括位于

the United States

美国

，

United Kingdom

英国

，

France

法国

，

the Netherlands

荷兰

，

Belgium

比利时

，

Germany

德国

，

Japan

日本

, and

，以及

China

中国

。

For more information, visit

欲了解更多信息，请访问

www.cryoportinc.com

or follow via LinkedIn at

或通过LinkedIn关注 at

https://www.linkedin.com/company/cryoportinc

or @cryoport on X, formerly known as Twitter at

或在X上@cryoport，之前称为Twitter

www.x.com/cryoport

for live updates.

获取实时更新。

Forward-Looking Statements

前瞻性声明

Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

本新闻稿中的声明并非纯粹的历史事实，包括有关Cryoport的意图、希望、信念、预期、陈述、预测、计划或未来预测的声明，均属于1995年《私人证券诉讼改革法案》所指的前瞻性声明。

These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the sale of CRYOPDP and the strategic collaboration with DHL, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements.

这些前瞻性陈述包括但不限于与Cryoport对出售CRYOPDP及与DHL战略协作未来收益的预期相关的陈述，包括其对未来收入和收入来源的潜在影响。需要注意的是，Cryoport的实际结果可能与任何此类前瞻性陈述中的内容存在重大差异。

Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks.

可能导致实际结果产生重大差异的因素包括但不限于：与不断变化的经济和地缘政治状况、供应链限制、通货膨胀压力、外汇波动影响、产品市场趋势、Cryoport现金流变化、市场接受风险以及技术开发风险相关的风险和不确定性。

Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the 'Risk Factors' section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements.

Cryoport的业务可能受到其SEC报告中讨论的其他因素的影响，包括其最近提交的Form 10-K和Form 10-Q定期报告中的“风险因素”部分，以及其随后向SEC提交的文件。本新闻稿中包含的前瞻性声明仅代表截至本日期的情况，Cryoport提醒投资者不要过度依赖这些前瞻性声明。

Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release..

除非法律要求，Cryoport否认任何义务，并且不承担更新或修改本新闻稿中任何前瞻性陈述的责任。

SOURCE Cryoport, Inc.

来源：Cryoport公司

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers